Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Post by Siberiaon Jan 10, 2022 10:56am
131 Views
Post# 34299812

THRM - COVID-19 Saliva Collection Kits Market

THRM - COVID-19 Saliva Collection Kits Market
Country-wise Insights: Why is the U.S. the Largest Market for COVID-19 Saliva Collection Kits? The U.S. dominates the North American region with a market share over 90% in 2021, and is expected to continue experiencing high growth throughout the forecast period. This can be mainly attributed to constant commercialization of innovative detection products together with ongoing developments in the field of immunoassay-based products, significant expansion of target patient population, and supportive government policies and their focus on new product development. More info at: https://www.persistencemarketresearch.com/market-research/covid-19-saliva-collection-kits-market.asp
<< Previous
Bullboard Posts
Next >>